Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cancer Chemotherapy and Pharmacology
Published in: Cancer Chemotherapy and Pharmacology 3/2018

01-09-2018 | Original Article

A phase I study of panobinostat in pediatric patients with refractory solid tumors, including CNS tumors

Authors: Paul J. Wood, Robyn Strong, Grant A. McArthur, Michael Michael, Elizabeth Algar, Andrea Muscat, Lin Rigby, Melissa Ferguson, David M. Ashley

Published in: Cancer Chemotherapy and Pharmacology | Issue 3/2018

Login to get access

Abstract

Purpose

This was an open label, phase I (3 + 3 design), multi-centre study evaluating panobinostat in pediatric patients with refractory solid tumors.

Methods

Primary endpoints were to establish MTD, define and describe associated toxicities, including dose limiting toxicities (DLT) and to characterize its pharmacokinetics (PK). Secondary endpoints included assessing the anti-tumour activity of panobinostat, and its biologic activity, by measuring acetylation of histones in peripheral blood mononuclear cells.

Results

Nine patients were enrolled and treated with intravenous panobinostat at a dosing level of 15 mg/m2 which was tolerated. Six were evaluable for adverse events. Two (33%) patients experienced Grade 3–4 thrombocytopenia, 1 (17%) experienced Grade 3 anemia, and 2 (33%) experienced Grade 3 neutropenia. Grade 4 drug related pain occurred in 2 (33%) of the patients studied. Two (33%) patients experienced a Grade 2 QTcF change (0.478 ± 0.006 ms). One cardiac DLT (T wave changes) was reported. PK values for 15 mg/m2 (n = 9) dosing were: Tmax 0.8 h, Cmax 235.2 ng/mL, AUC0–t 346.8 h ng/mL and t1/2 7.3 h. Panobinostat significantly induced acetylation of histone H3 and H4 at all time points measured when compared to pre-treatment samples (p < 0.05). Pooled quantitative Western blot data confirmed that panobinostat significantly induced acetylation of histone H4 at 6 h (p < 0.01), 24 h (p < 0.01) and 28–70 h (p < 0.01) post dose.

Conclusion

A significant biological effect of panobinostat, measured by acetylation status of histone H3 and H4, was achieved at a dose of 15 mg/m2. PK data and drug tolerability at 15 mg/m2 was similar to that previously published.
Literature
1.
2.
Yoshida M, Furumai R, Nishiyama M et al (2001) Histone deacetylase as a new target for cancer chemotherapy. Cancer Chemother Pharmacol 48(Suppl 1):S20–S26CrossRefPubMed
3.
Marks P, Rifkind R, Richon V et al (2001) Histone deacetylases and cancer: causes and therapies. Nat Rev 1:194–202CrossRef
4.
Weidle UH, Grossmann A (2000) Inhibition of histone deacetylases: a new strategy to target epigenetic modifications for anticancer treatment. Anticancer Res 20(3A):1471–1485PubMed
5.
6.
Deckert J, Struhl K (2001) Histone acetylation at promoters is differentially affected by specific activators and repressors. Mol Cell Biol 21(8):2726–2735CrossRefPubMedPubMedCentral
7.
8.
Giles RH, Peters DJ, Breuning MH (1998) Conjunction dysfunction: CBP/p300 in human disease. Trends Genet 14(5):178–183CrossRefPubMed
9.
Gayther SA, Batley SJ, Linger L et al (2000) Mutations truncating the EP300 acetylase in human cancers. Nat Genet 24(3):300–303CrossRefPubMed
10.
Murata T, Kurokawa R, Krones A et al (2001) Defect of histone acetyltransferase activity of the nuclear transcriptional coactivator CBP in Rubinstein–Taybi syndrome. Hum Mol Genet 10(10):1071–1076CrossRefPubMed
11.
Sakai K, Nagahara H, Abe K et al (1992) Loss of heterozygosity on chromosome 16 in hepatocellular carcinoma. J Gastroenterol Hepatol 7(3):288–292CrossRefPubMed
12.
Rowley JD, Reshmi S, Sobulo O et al (1997) All patients with the T(11;16)(q23;p13.3) that involves MLL and CBP have treatment-related hematologic disorders. Blood 90(2):535–541PubMed
13.
Irminger-Finger I, Siegel BD, Leung WC (1999) The functions of breast cancer susceptibility gene 1 (BRCA1) product and its associated proteins. J Biol Chem 380(2):117–128
14.
Kutko MC, Glick RD, Butler LM et al (2003) Histone deacetylase inhibitors induce growth suppression and cell death in human rhabdomyosarcoma in vitro. Clin Cancer Res 9(15):5749–5755PubMed
15.
Feinberg AP, Cui H, Ohlsson R (2002) DNA methylation and genomic imprinting: insights from cancer into epigenetic mechanisms. Semin Cancer Biol 12(5):389–398CrossRefPubMed
16.
Waldeck K, Cullinane C, Ardley K et al (2016) Long term, continuous exposure to panobinostat induces terminal differentiation and long term survival in the TH-MYCN neuroblastoma mouse model. Int J Cancer 139(1):194–204CrossRefPubMed
17.
18.
Cain JE, McCaw A, Jayasekara WS et al (2013) Sustained low-dose treatment with the histone deacetylase inhibitor LBH589 induces terminal differentiation of osteosarcoma cells. Sarcoma 2013:608964CrossRefPubMedPubMedCentral
19.
Coffey DC, Kutko MC, Glick RD et al (2001) The histone deacetylase inhibitor, CBHA, inhibits growth of human neuroblastoma xenografts in vivo, alone and synergistically with all-trans retinoic acid. Cancer Res 7(8):3591–3594
20.
Coffey DC, Kutko MC, Glick RD et al (2000) Histone deacetylase inhibitors and retinoic acids inhibit growth of human neuroblastoma in vitro. Med Pediatr Oncol 35(6):577–581CrossRefPubMed
21.
Glick RD, Swendeman SL, Coffey DC et al (1999) Hybrid polar histone deacetylase inhibitor induces apoptosis and CD95/CD95 ligand expression in human neuroblastoma. Cancer Res 59(17):4392–4399PubMed
22.
Biegel JA, Kalpana G, Knudsen ES et al (2002) The role of INI1 and the SWI/SNF complex in the development of rhabdoid tumours: meeting summary from the workshop on childhood atypical teratoid/rhabdoid tumours. Cancer Res 62(1):323–328PubMed
23.
Prince HM, George D, Patnaik A et al (2007) Phase I study of oral LBH589, a novel deacetylase (DAC) inhibitor in advanced solid tumours and non-Hodgkins lymphoma. J Clin Oncol 25(18S):3500
24.
Children’s Oncology Group, Fouladi M, Furman WL et al (2006) Phase I study of depsipeptide in pediatric patients with refractory solid tumors: a Children’s Oncology Group report. J Clin Oncol 24(22):3678–3685CrossRef
25.
Fouladi M, Park JR, Stewart CF et al (2010) Pediatric phase I trial and pharmacokinetic study of vorinostat: a Children’s Oncology Group phase I consortium report. J Clin Oncol 28(22):3623–3629CrossRefPubMedPubMedCentral
26.
Chan K, Fang D, Gan H et al (2013) The histone H3.3K27M mutation in pediatric glioma reprograms H3K27 methylation and gene expression. Genes Dev 27:985–990CrossRefPubMedPubMedCentral
27.
28.
29.
Ronzoni S, Faretta M, Ballarini M et al (2005) New method to detect histone acetylation levels by flow cytometry. Cytometry 66A:52–61CrossRef
30.
Sharma S, Beck J, Mita M et al (2013) A phase I dose-escalation study of intravenous panobinostat in patients with lymphoma and solid tumors. Invest New Drugs 31(4):974–985CrossRefPubMed
31.
Anne M, Sammartino D, Barginear M et al (2013) Profile of panobinostat and its potential for treatment in solid tumors: an update. Onco Targets Ther 6:1613–1624CrossRefPubMedPubMedCentral
32.
Giles F, Fischer T, Cortes J et al (2006) A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies. Clin Cancer Res 12:4628–4635CrossRefPubMed
33.
Graham C, Tucker C, Creech J et al (2006) Evaluation of the antitumor efficacy, pharmacokinetics, and pharmacodynamics of the histone deacetylase inhibitor depsipeptide in childhood cancer models in vivo. Clin Cancer Res 12(1):223–234CrossRefPubMed
34.
35.
Prince HM, Bishton M (2009) Panobinostat (LBH589): a novel pan-deacetylase inhibitor with activity in T cell lymphoma. Hematol Meet Rep 3(1):33–38
Metadata
Title
A phase I study of panobinostat in pediatric patients with refractory solid tumors, including CNS tumors
Authors
Paul J. Wood
Robyn Strong
Grant A. McArthur
Michael Michael
Elizabeth Algar
Andrea Muscat
Lin Rigby
Melissa Ferguson
David M. Ashley
Publication date
01-09-2018
Publisher
Springer Berlin Heidelberg
Published in
Cancer Chemotherapy and Pharmacology / Issue 3/2018
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-018-3634-4

Other articles of this Issue 3/2018

Cancer Chemotherapy and Pharmacology 3/2018 Go to the issue

Original Article

Efficacy and safety of liposome-paclitaxel and carboplatin based concurrent chemoradiotherapy for locally advanced lung squamous cell carcinoma

Short Communication

A population pharmacokinetic/toxicity model for the reduction of platelets during a 48-h continuous intravenous infusion of the histone deacetylase inhibitor belinostat

Original Article

Lapatinib in combination with paclitaxel plays synergistic antitumor effects on esophageal squamous cancer

Review Article

Natural low- and high-density lipoproteins as mighty bio-nanocarriers for anticancer drug delivery

Original Article

Correlation of plasma erlotinib trough concentration with skin rash in Chinese NSCLC patients harboring exon 19 deletion mutation

Original Article

A phase I pharmacokinetic and pharmacodynamic study of GTI-2040 in combination with gemcitabine in patients with solid tumors
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits